Biweekly THP‐COP therapy for newly diagnosed peripheral T‐cell lymphoma patients

Abstract

Pirarubicin tetrahydropyranyl adriamycin (THP-ADR) is an analogue of doxorubicin. This agent exhibits activity against some doxorubicin-resistant cell lines. We performed a phase II study of biweekly THP-COP [50 mg/m(2) pirarubicin, 750 mg/m(2) cyclophosphamide, 1.4 mg/m(2) vincristine (2.0 mg maximum) on day 1, and 100 mg/body predonisolone on days 1-5] in patients with peripheral T-cell lymphoma (PTCL). Seventeen patients with newly diagnosed PTCL were enrolled. Histological diagnoses were of PTCL, not otherwise specified (n = 5), or angioimmunoblastic T-cell lymphoma (n = 12). All diagnostic specimens including those of the historical control group were centrally reviewed by hematological pathologists. All patients received six cycles of biweekly THP-COP. The patient group included 13 male and 4 female patients, with a median age of 62 years. The median follow-up time in surviving patients was 30 months. Overall response rate was 94% with 15 cases of complete remission (88%). The 3-year progression-free survival and overall survival rates were 57% and 75%, respectively. The most frequent adverse events associated with biweekly THP-COP were leukocytopenia (100%), neutropenia (100%), and lymphopenia (100%), followed by alopecia (92%) and anaemia (88%). All of these occurred only transiently, and the patients subsequently recovered. Biweekly THP-COP is a safe and promising therapy for patients with newly diagnosed PTCL. This study is registered in a public database (UMIN000010485).

CHOP or THP‐COP regimens in the treatment of newly diagnosed peripheral T‐cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin

“…Hence, we could not simply compare our results with those of the JGTLE study. Tomita et al reported that biweekly THP‐COP therapy was a safe and promising therapy for patients with PTCL‐NOS and AITL (CR rate, 88%; 3 year‐OS, 75%) by a prospective phase II study . These results seem to be superior to our results.…”

“…Furthermore, the Japanese Clinical Study Group of THP Lymphomas in the Elderly (JGTLE) reported that elderly T‐cell lymphomas had a significantly better response to THP‐COP than to CHOP, whereas no such difference was observed in B‐cell lymphoma . In addition, Tomita et al recently reported encouraging results of a phase II study of THP‐COP therapy for newly diagnosed PTCL patients . However, this phase II study was a single arm trial of THP‐COP and consisted of a small number of cases ( n = 17) including only five PTCL‐NOS.…”

Serum ferritin level is a prognostic marker in patients with peripheral T‐cell lymphoma

“…The PTCL subtypes were PTCL, NOS (39 patients) and AITL (39 patients). The primary treatment regimens were cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; 14 patients); pirarubicin, cyclophosphamide, vincristine, and prednisone (THP‐COP; 44 patients); THP‐COP followed by radiotherapy (three patients); up‐front autologous peripheral blood stem cell transplantation (three patients); and THP‐COP at 2‐week intervals in a clinical trial (14 patients) . The median serum ferritin level was 183 ng/mL (range, 5–14 622 ng/mL).…”

Bilateral ptosis as first presentation of cytophagic histiocytic panniculitis: a case report

“…Therefore, the treatment was switched to chemotherapy. Though CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) [5] is the most common chemotherapy regimen, we decided to use THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone) for its proven superior efficacy. Pirarubicin (THP) is an analogue of doxorubicin [5].…”

“…Though CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) [5] is the most common chemotherapy regimen, we decided to use THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone) for its proven superior efficacy. Pirarubicin (THP) is an analogue of doxorubicin [5]. Significant improvement was noticed after three cycles of chemotherapy, with partially recovery of ptosis, eye movements, and decreased pupil diameters (Fig.…”